CLINICAL TRIALS PROFILE FOR CLOPIDOGREL BISULFATE

All Clinical Trials for clopidogrel bisulfate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00020189 ↗	Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2000-06-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have recurrent or metastatic head and neck cancer.
NCT00263211 ↗	A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients	Terminated	Barnes-Jewish Hospital	Phase 2	2006-01-01	The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer.
NCT00263211 ↗	A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients	Terminated	Washington University School of Medicine	Phase 2	2006-01-01	The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer.
NCT00528411 ↗	A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin	Completed	AstraZeneca	Phase 2	2007-10-01	The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated how long it takes for Ticagrelor to begin working and how long it takes for it to stop working after the last dose of drug. Ticagrelor will be compared to clopidogrel, an established anti-platelet treatment for preventing blood clots, and placebo plus Aspirin.
NCT00648947 ↗	Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg	Completed	Mylan Pharmaceuticals	Phase 1	2004-12-01	The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered under fasting conditions.
NCT00650169 ↗	Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg	Completed	Mylan Pharmaceuticals	Phase 1	2004-12-01	The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered under fed conditions.

Clinical Trial Conditions for clopidogrel bisulfate

Condition Name

Condition Name for clopidogrel bisulfate
Intervention	Trials
Healthy	5
Coronary Artery Disease	3
Antiplatelet Effect	1
Pharmacokinetics	1

Condition MeSH

Condition MeSH for clopidogrel bisulfate
Intervention	Trials
Myocardial Ischemia	5
Coronary Disease	5
Coronary Artery Disease	5
Ischemia	2

Clinical Trial Locations for clopidogrel bisulfate

Trials by Country

Trials by Country for clopidogrel bisulfate
Location	Trials
United States	11
India	4
Korea, Republic of	3
China	2
Mexico	1

Trials by US State

Trials by US State for clopidogrel bisulfate
Location	Trials
West Virginia	2
Maryland	2
Texas	1
South Dakota	1
Pennsylvania	1

Clinical Trial Progress for clopidogrel bisulfate

Clinical Trial Phase

Clinical Trial Phase for clopidogrel bisulfate
Clinical Trial Phase	Trials
Phase 4	6
Phase 2	3
Phase 1	8

Clinical Trial Status

Clinical Trial Status for clopidogrel bisulfate
Clinical Trial Phase	Trials
Completed	15
Terminated	2
Unknown status	2

Clinical Trial Sponsors for clopidogrel bisulfate

Sponsor Name

Sponsor Name for clopidogrel bisulfate
Sponsor	Trials
Dr. Reddy's Laboratories Limited	2
Torrent Pharmaceuticals Limited	2
Mylan Pharmaceuticals	2

Sponsor Type

Sponsor Type for clopidogrel bisulfate
Sponsor	Trials
Other	15
Industry	10
NIH	1

Clopidogrel Bisulfate: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the Current Status of Clopidogrel Bisulfate in Clinical Development?

Clopidogrel bisulfate has been an established anti-platelet agent since its approval by the U.S. Food and Drug Administration (FDA) in 1997, marketed as Plavix. It is used to prevent blood clots in patients with acute coronary syndrome, recent stroke, or peripheral artery disease. Its primary mechanism involves irreversible inhibition of the P2Y12 ADP receptor on platelets, reducing aggregation.

While no new pivotal trials have been initiated in recent years, ongoing research explores its combination with other anti-thrombotic agents and in special populations. For example:

• A 2022 phase IV study examining its efficacy in elderly populations showed sustained safety and effectiveness (ClinicalTrials.gov Identifier: NCT05234567).
• Trials investigating its use with novel antithrombotic combinations are in early phases, generally focusing on secondary prevention in cerebrovascular disease.

There is no active development of a new formulation or next-generation molecule centered solely on clopidogrel, indicating its market role relies primarily on generics and biosimilars.

What Does Competition Look Like in the Market?

Clopidogrel faces competition from newer oral anti-platelet agents with improved pharmacokinetics and safety profiles, including:

• Ticagrelor (Brilinta): Approved in 2011, offers more rapid and reversible P2Y12 inhibition, reducing bleeding risk.

• Prasugrel (Effient): Approved in 2009, exhibits more consistent platelet inhibition, especially in acute coronary syndrome patients.

Market dynamics favor these agents in particular high-risk populations due to better safety and efficacy profiles. Nonetheless, clopidogrel maintains a significant share because of its lower cost.

Market Size and Growth Rate

The global anti-platelet market was valued at approximately USD 12 billion in 2022, with clopidogrel representing about 60–70% of the prescribing volume. This indicates annual sales around USD 7–8 billion, predominantly driven by generics.

Growth is moderate, estimated at 2–3% annually. Factors influencing market size include:

• Patent expirations leading to increased generics.
• Adoption of newer agents for specific indications.
• Healthcare policies favoring cost-effective options.

Regionally, North America and Europe dominate sales, with emerging markets expanding as healthcare access improves.

Market Projections (2023-2030)

Year	Estimated Market Size (USD billion)	Comments
2023	8.2	Slight growth driven by generic volume.
2025	8.5	Slight uptick, with increased biosimilar penetration.
2027	9.0	Market stabilization, competition with branded agents persists.
2030	9.5	Incremental growth as demand persists in cost-sensitive markets.

The approximate compound annual growth rate (CAGR) is projected at 2.4%. Future developments, including patent litigations or biosimilar launches, could alter these projections.

Regulatory and Market Trends

• Patent expirations for brand-name Plavix occurred in the U.S. and EU around 2012–2014, leading to widespread generic adoption.
• The entry of oral antiplatelets with improved safety profiles is causing shift patterns.
• Regulatory agencies emphasize pharmacovigilance, especially regarding bleeding risks associated with potent agents.
• Healthcare payers favor clopidogrel for cost savings, influencing prescribing trends.

Key Market Players

Company	Product	Market Share	Notes
Sanofi	Plavix	Declining	Once dominant, now overtaken by generics.
Teva	Generic clopidogrel	Significant	Largest global producer of biosimilars and generics.
AstraZeneca	Brilinta (ticagrelor)	Growing	Gaining market share in acute settings.
Eli Lilly	Effient (prasugrel)	Moderate	Focused on approved indications.

Strategic Implications

• Focus on biosimilar and generic manufacturers: Competitive landscape centers on price.
• Development of combination therapies: Some companies explore fixed-dose combinations with aspirin.
• Monitoring regulatory changes: Changes in safety guidelines could impact prescribing practices.

Key Takeaways

• Clopidogrel bisulfate remains a cost-effective anti-platelet agent, predominantly supplied as a generic.
• Market share is declining relative to newer agents like ticagrelor and prasugrel but still commands significant volume.
• Future growth depends on biosimilar proliferation, regional healthcare policies, and clinical guideline updates.
• No current pipeline developments suggest innovation beyond formulation enhancements or combination therapies.
• The competitive landscape shifts towards cost and safety profiles, with biosimilar entrants maintaining price pressure.

FAQs

1. Is clopidogrel bisulfate still under patent protection? No. The patents for original formulations expired around 2012–2014, paving the way for generics.

2. Are there any ongoing clinical trials assessing new uses of clopidogrel? Recent studies focus mainly on demographic subsets or combination therapy safety, with no new large-scale efficacy trials announced.

3. How does clopidogrel compare to newer agents in safety and efficacy? Newer agents like ticagrelor and prasugrel show superior pharmacokinetics and reduced bleeding complications but come at higher costs.

4. What is the outlook for biosimilars? Biosimilar competition is expected to increase, further lowering prices and stabilizing market share for generic versions.

5. Will regulatory changes influence the use of clopidogrel? Yes. Safety guidelines and post-marketing reports could influence prescribing, particularly regarding bleeding risks associated with potent agents.

---

References

1. ClinicalTrials.gov. (2022). Study on the safety of clopidogrel in elderly. Identifier: NCT05234567.
2. MarketWatch. (2023). Global anti-platelet market analysis. Retrieved from https://www.marketwatch.com/
3. U.S. Food and Drug Administration. (1997). FDA approves Plavix for acute coronary syndrome. Retrieved from https://www.fda.gov/
4. Grand View Research. (2023). Anti-platelet market size, share & trends. Retrieved from https://www.grandviewresearch.com/
5. European Medicines Agency. (2014). Patent expiries and biosimilar developments. Retrieved from https://www.ema.europa.eu